Treatment Patterns and Healthcare Resource Use in Medicare Beneficiaries with Parkinson's Disease.

Yan SongJian-Yu ETracy GuoRahul SasaneSteve ArconaNirmal KeshavaEric Wu

Published in: ClinicoEconomics and outcomes research : CEOR (2023)

While levodopa is still the mainstay of PD management, considerable heterogeneity exists in real-world treatment patterns. Overall, PD symptoms and AEs were associated with significantly higher HRU and healthcare costs, suggesting unmet medical needs for PD treatments with better tolerability profiles.

Keyphrases

healthcare
parkinson disease
single cell
open label
deep brain stimulation
replacement therapy
social media
health information